Megan Lynch/LinkedIn
Jun 16, 2026, 16:17
Megan Lynch: Thrilled to Join AstraZeneca
Megan Lynch, Global Product Leader, Cell Therapy Enterprise at AstraZeneca, shared a post on LinkedIn:
“I’m thrilled to share that I’m joining AstraZeneca as a Global Product Leader, Cell Therapy Enterprise.
Cell therapy is transforming how we treat patients across hem/onc, autoimmune, and rare disease.
Getting innovative medicines to patients and providers has always been my north star and I can’t wait to dig in.
Thank you to Margie Li, Margaret DiGuardo, Carsten Linnemann, Craig Maxwell, and Eva Piqué for your partnership throughout this process — I’m looking forward to what we’ll build together.
Here’s to what’s next.”

Stay updated with Hemostasis Today.
-
Nov 17, 2026, 15:26Hereditary Hemorrhagic Telangiectasia: The Molecular Connection Between Vascular Malformations and Bleeding
-
Nov 17, 2026, 14:54Cindy Neunert: Beyond Platelet Counts – Addressing Fatigue and Whole-Person Care in ITP
-
Nov 17, 2026, 14:44Strengthening Haemophilia Diagnosis Through Hands-On Laboratory Training – IAHAD
-
Nov 17, 2026, 14:40Platelet Membrane Protrusions Beyond Their Role in Hemostasis – JTH
-
Nov 17, 2026, 14:10Wolfgang Miesbach: Aspirin vs Anticoagulants – Who Needs More Than Aspirin?
-
Nov 17, 2026, 14:08Chaza Alaji: Soluble Transferrin Receptor – A Key to Uncovering Hidden Iron Deficiency
-
Nov 17, 2026, 14:03Shadi Tabibian: Fibrinogen – From Molecular Structure to Clinical Decision Making
-
Nov 17, 2026, 13:54Gabrielle Sarlon: Breaking the Silence on Menstrual Bleeding During Anticoagulant Therapy
-
Nov 17, 2026, 13:47Ksenia Guznova Kats: Advanced Venous Stenting in May–Thurner Syndrome